Source: BEFREE

Gene Disease Score gda Association Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 29126
Gene Symbol: CD274
CD274
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.400 AlteredExpression BEFREE We studied whether HCC cell expression of MEF2D regulates expression of PD-L1 in response to IFNG. 31678303

2020

Entrez Id: 29126
Gene Symbol: CD274
CD274
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.400 Biomarker BEFREE In recent years, immune checkpoint inhibitors (anti-PD-1, anti-PD-L1, and anti-CTLA-4 antibodies) have exhibited potential therapeutic effects for advanced HCC. 31811905

2020

Entrez Id: 29126
Gene Symbol: CD274
CD274
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.400 Biomarker BEFREE Concomitant with patient-derived M-MDSC suppression by i-BET762, combined treatment with anti-PD-L1 synergistically enhanced TILs, resulting in tumour eradication and prolonged survival in the fibrotic-HCC mouse model. 31076403

2020

Entrez Id: 29126
Gene Symbol: CD274
CD274
CUI: C2239176
Disease: Liver carcinoma
Liver carcinoma
0.400 Biomarker BEFREE Finally, using SP263, the mean number of PD-L1-positive cells was 11.3 ± 12.6 in HCC from deceased patients, versus 4.7 ± 5.2 in alive patients (p = 0.039). 31767125

2020

Entrez Id: 29126
Gene Symbol: CD274
CD274
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.400 Biomarker BEFREE The clinical therapy that dilapidates PD1 or PD-L1-mediated cancer tolerance has pushed out the need to uncover the molecular regulation of PD-L1 overexpression in the tumor cell. 30385408

2019

Entrez Id: 29126
Gene Symbol: CD274
CD274
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.400 Biomarker BEFREE Immunotherapy targeting immune checkpoints, such as PD-L1, has demonstrated significant success in controlling numerous malignancies. 31030234

2019

Entrez Id: 29126
Gene Symbol: CD274
CD274
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.400 Biomarker BEFREE The combination of PD-1/PD-L1 blockade and macrophage-targeted therapy will exert synergetic anti-tumor effect and shape the future of cancer immunology and immunotherapy. 30963235

2019

Entrez Id: 29126
Gene Symbol: CD274
CD274
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.400 Biomarker BEFREE Programmed death ligand-1 (PD-L1) in conjunction with tumor-infiltrating lymphocytes (TILs) has been studied as a potential mechanism of "immune escape" in several human malignancies. 30085020

2019

Entrez Id: 29126
Gene Symbol: CD274
CD274
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.400 PosttranslationalModification BEFREE IL-6/JAK1 pathway drives PD-L1 Y112 phosphorylation to promote cancer immune evasion. 31305264

2019

Entrez Id: 29126
Gene Symbol: CD274
CD274
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.400 Biomarker BEFREE Among these checkpoints are tytotoxic T-lymphocyte-associated antigen 4, checkpoints programmed death-1 and programmed death-ligand 1; their blockades have been approved by the Food and Drug Administration for therapy of melanoma and other types of cancers. 30137232

2019

Entrez Id: 29126
Gene Symbol: CD274
CD274
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.400 Biomarker BEFREE Immunohistochemical expression of HDAC6, hypoxia inducible factors-1α (HIF-1α), programmed death-1 ligand (PD-L1), CD44 (cancer stem cell marker), and ARID1A was analysed for 106 OCCC patients. 30787326

2019

Entrez Id: 29126
Gene Symbol: CD274
CD274
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.400 Biomarker BEFREE Our study suggests that blocking PD1/PDL1 pathway may become an effective mode of treatment in cancer immunotherapy especially for Renal Cell Carcinomas. 31653140

2019

Entrez Id: 29126
Gene Symbol: CD274
CD274
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.400 AlteredExpression BEFREE Mut-p53-induced epithelial-mesenchymal transition (EMT) plays a crucial role in the invasion and metastasis of endocrine carcinomas, and Mut-p53 is involved in cancer immune evasion by upregulating PD-L1 expression. 30915036

2019

Entrez Id: 29126
Gene Symbol: CD274
CD274
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.400 Biomarker BEFREE The success of T cell-directed checkpoint inhibitors of CTLA-4 and PD-1/PD-L1 has opened a new approach for cancer immunotherapy and resulted in extensive research on immune checkpoints. 31681269

2019

Entrez Id: 29126
Gene Symbol: CD274
CD274
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.400 Biomarker BEFREE Safety and Tolerability of Immune Checkpoint Inhibitors (PD-1 and PD-L1) in Cancer. 30649742

2019

Entrez Id: 29126
Gene Symbol: CD274
CD274
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.400 Biomarker BEFREE Anti-programmed cell death 1 (PD-1) and anti-programmed cell death ligand 1 (PD-L1) antibodies are novel immunotherapies for cancer that can induce immune-related adverse events (irAEs). 30528137

2019

Entrez Id: 29126
Gene Symbol: CD274
CD274
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.400 Biomarker BEFREE Currently, the strategy of PD-1/ PD-L1 blockade has already been applied to clinical cancer therapy, providing evidences that PD-1 signal is one of the main factors of cancer immune escape in humans. 28929192

2019

Entrez Id: 29126
Gene Symbol: CD274
CD274
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.400 Biomarker BEFREE Although both anti-PD-1 antibody and treatments using anti-PD-L1 antibody are currently in clinical use, their therapeutic effects vary according to cancer type. 31040694

2019

Entrez Id: 29126
Gene Symbol: CD274
CD274
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.400 Biomarker BEFREE Expert opinion: Data supporting the patent demonstrate the ability of LAG-3Ig and PD-1/PD-L1 to be useful in T cells activation, in addition to the reports showing that LAG-3 and anti-PD-1 and PD-L1 antibodies are therapeutic agents against cancer. 30990738

2019

Entrez Id: 29126
Gene Symbol: CD274
CD274
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.400 Biomarker BEFREE Building on the anti-PD1/PD-L1 backbone: combination immunotherapy for cancer. 31359805

2019

Entrez Id: 29126
Gene Symbol: CD274
CD274
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.400 Biomarker BEFREE Importantly, changes in immunosuppressive MDSCs frequency and PD-L1 expression levels may serve as biomarkers of hypoxia levels in cancer affected tissues that can benefit from hyperoxia treatments. 30949408

2019

Entrez Id: 29126
Gene Symbol: CD274
CD274
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.400 Biomarker BEFREE Molecular predictors of response to PD-1/PD-L1 inhibition in urothelial cancer. 30374610

2019

Entrez Id: 29126
Gene Symbol: CD274
CD274
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.400 Biomarker BEFREE A total of 7359 articles related to PD-1 and PD-L1 research in the field of cancer were identified. 31030093

2019

Entrez Id: 29126
Gene Symbol: CD274
CD274
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.400 Biomarker BEFREE Targeting PD-1/PD-L1 to treat cancer has shown benefits in many patients, suggesting a promising opportunity to target this pathway in autoimmune and inflammatory disorders. 31636634

2019

Entrez Id: 29126
Gene Symbol: CD274
CD274
CUI: C0006826
Disease: Malignant Neoplasms
Malignant Neoplasms
0.400 Biomarker BEFREE Although many antibodies targeting PD-1/PD-L1 have been developed to block their interaction for the treatment of cancer, the reduced response rate and resistance to the therapies call for further comprehension of this pathway in the tumor microenvironment. 31748880

2019